Directors of the California stem cell agency this morning unanimously approved a $50 million foray – its first-ever — into the financing of clinical trials.
The program appears likely to be of benefit to only a handful of organizations – particularly the three that have pluripotent proposals that are now on hold with the FDA. The names of the enterprises were not disclosed during the board